Watson buys Arrow for $1.75B

It's not just Big Pharma that's eyeing international expansion. Generics maker Watson Pharmaceuticals has agreed to buy Arrow Group, another maker of copycat meds with tentacles in more than 20 countries. The price: $1.75 billion. The result: A combined company with annual revenues of more than $3 billion. The payoff: Watson predicts the deal will increase earnings next year. Watson report

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.